AR079164A1 - Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. - Google Patents
Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.Info
- Publication number
- AR079164A1 AR079164A1 ARP100104362A ARP100104362A AR079164A1 AR 079164 A1 AR079164 A1 AR 079164A1 AR P100104362 A ARP100104362 A AR P100104362A AR P100104362 A ARP100104362 A AR P100104362A AR 079164 A1 AR079164 A1 AR 079164A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- alkoxy
- alkyl
- substituents selected
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 14
- 125000001424 substituent group Chemical group 0.000 abstract 14
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000003277 amino group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- -1 cyclic amine Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005111 carboxyalkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009268040 | 2009-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079164A1 true AR079164A1 (es) | 2011-12-28 |
Family
ID=44066507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104362A AR079164A1 (es) | 2009-11-25 | 2010-11-25 | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8299070B2 (enExample) |
| EP (3) | EP3766877A1 (enExample) |
| JP (6) | JP5734628B2 (enExample) |
| KR (1) | KR101766502B1 (enExample) |
| CN (1) | CN102712624B (enExample) |
| AR (1) | AR079164A1 (enExample) |
| AU (1) | AU2010323579C1 (enExample) |
| BR (1) | BR112012012529B1 (enExample) |
| CA (1) | CA2781660C (enExample) |
| CL (1) | CL2012001328A1 (enExample) |
| CO (1) | CO6541645A2 (enExample) |
| CY (1) | CY1117559T1 (enExample) |
| DK (1) | DK2505586T3 (enExample) |
| ES (1) | ES2572935T3 (enExample) |
| HR (1) | HRP20160579T1 (enExample) |
| HU (1) | HUE028016T2 (enExample) |
| IL (1) | IL220009A (enExample) |
| ME (1) | ME02447B (enExample) |
| MX (1) | MX2012006017A (enExample) |
| MY (1) | MY161095A (enExample) |
| NZ (1) | NZ600840A (enExample) |
| PE (1) | PE20121358A1 (enExample) |
| PH (1) | PH12012501021A1 (enExample) |
| PL (1) | PL2505586T3 (enExample) |
| PT (1) | PT2505586E (enExample) |
| RS (1) | RS54910B1 (enExample) |
| RU (1) | RU2556216C2 (enExample) |
| SI (1) | SI2505586T1 (enExample) |
| SM (1) | SMT201600258B (enExample) |
| TW (1) | TWI491591B (enExample) |
| WO (1) | WO2011065402A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| SG11201503459SA (en) * | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| CN103804364A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| CN103800337A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804272A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804351A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804302A (zh) * | 2012-11-14 | 2014-05-21 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| AR099936A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| WO2016002918A1 (ja) * | 2014-07-04 | 2016-01-07 | 日本たばこ産業株式会社 | インドール化合物の製造方法 |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| CN104356086A (zh) * | 2014-11-28 | 2015-02-18 | 湖南科技大学 | 一种适于工业生产3-吗啉酮的制备方法 |
| CN112135615B (zh) * | 2018-05-25 | 2023-10-31 | 日本烟草产业株式会社 | 包含吲哚类化合物的肾病综合征治疗或预防剂 |
| CA3100675A1 (en) * | 2018-05-25 | 2019-11-28 | Japan Tobacco Inc. | Method of treating pain or interstitial cystitis using indole compound |
| WO2019225740A1 (ja) | 2018-05-25 | 2019-11-28 | 日本たばこ産業株式会社 | インドール化合物を含む多発性硬化症の治療又は予防剤 |
| KR20220118525A (ko) | 2019-12-20 | 2022-08-25 | 화이자 인코포레이티드 | 벤즈이미다졸 유도체 |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| CA3205023A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease |
| WO2022130171A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease |
| US20240279202A1 (en) * | 2021-05-03 | 2024-08-22 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| CN117794927A (zh) * | 2021-06-11 | 2024-03-29 | 伊迪亚生物科学有限公司 | 作为DNA聚合酶θ抑制剂的O-连接噻二唑基化合物 |
| AU2022370351A1 (en) * | 2021-10-19 | 2024-05-02 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway |
| AU2024251390A1 (en) | 2023-04-13 | 2025-11-27 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US953411A (en) * | 1908-09-02 | 1910-03-29 | Erastus De Moulin | Trick weight-lifting machine. |
| IL161576A0 (en) * | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| DE60305446T4 (de) * | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| FR2854159B1 (fr) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2005026175A1 (en) | 2003-09-08 | 2005-03-24 | Aventis Pharmaceuticals Inc. | Thienopyrazoles |
| KR20080011199A (ko) * | 2005-04-19 | 2008-01-31 | 교와 핫꼬 고교 가부시끼가이샤 | 질소 함유 복소환 화합물 |
| WO2007076228A2 (en) | 2005-12-20 | 2007-07-05 | Boehringer Ingelheim International Gmbh | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| GB0602178D0 (en) | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| US8604031B2 (en) * | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| JP2009268040A (ja) | 2008-04-23 | 2009-11-12 | Teruhiko Daiho | ループアンテナ装置 |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
-
2010
- 2010-11-24 US US12/954,438 patent/US8299070B2/en active Active
- 2010-11-25 DK DK10833248.7T patent/DK2505586T3/en active
- 2010-11-25 CA CA2781660A patent/CA2781660C/en active Active
- 2010-11-25 JP JP2010262058A patent/JP5734628B2/ja active Active
- 2010-11-25 WO PCT/JP2010/070988 patent/WO2011065402A1/ja not_active Ceased
- 2010-11-25 ES ES10833248.7T patent/ES2572935T3/es active Active
- 2010-11-25 PL PL10833248.7T patent/PL2505586T3/pl unknown
- 2010-11-25 PT PT108332487T patent/PT2505586E/pt unknown
- 2010-11-25 RS RS20160385A patent/RS54910B1/sr unknown
- 2010-11-25 EP EP20189306.2A patent/EP3766877A1/en not_active Withdrawn
- 2010-11-25 KR KR1020127016311A patent/KR101766502B1/ko active Active
- 2010-11-25 BR BR112012012529-0A patent/BR112012012529B1/pt active IP Right Grant
- 2010-11-25 PH PH1/2012/501021A patent/PH12012501021A1/en unknown
- 2010-11-25 PE PE2012000713A patent/PE20121358A1/es active IP Right Grant
- 2010-11-25 TW TW099140715A patent/TWI491591B/zh active
- 2010-11-25 HU HUE10833248A patent/HUE028016T2/en unknown
- 2010-11-25 SI SI201031188A patent/SI2505586T1/sl unknown
- 2010-11-25 EP EP16158053.5A patent/EP3059234A1/en not_active Withdrawn
- 2010-11-25 MX MX2012006017A patent/MX2012006017A/es active IP Right Grant
- 2010-11-25 RU RU2012126129/04A patent/RU2556216C2/ru active
- 2010-11-25 NZ NZ600840A patent/NZ600840A/en unknown
- 2010-11-25 AR ARP100104362A patent/AR079164A1/es active IP Right Grant
- 2010-11-25 ME MEP-2016-107A patent/ME02447B/me unknown
- 2010-11-25 EP EP10833248.7A patent/EP2505586B1/en active Active
- 2010-11-25 MY MYPI2012002292A patent/MY161095A/en unknown
- 2010-11-25 HR HRP20160579TT patent/HRP20160579T1/hr unknown
- 2010-11-25 CN CN201080062299.3A patent/CN102712624B/zh active Active
- 2010-11-25 AU AU2010323579A patent/AU2010323579C1/en active Active
-
2012
- 2012-05-23 CL CL2012001328A patent/CL2012001328A1/es unknown
- 2012-05-24 IL IL220009A patent/IL220009A/en active IP Right Grant
- 2012-06-22 CO CO12105036A patent/CO6541645A2/es active IP Right Grant
- 2012-09-26 US US13/627,047 patent/US20130116240A1/en not_active Abandoned
-
2015
- 2015-04-15 JP JP2015083457A patent/JP2015172051A/ja not_active Ceased
-
2016
- 2016-05-26 CY CY20161100462T patent/CY1117559T1/el unknown
- 2016-08-03 SM SM201600258T patent/SMT201600258B/it unknown
- 2016-10-20 JP JP2016205949A patent/JP2017039761A/ja not_active Ceased
- 2016-10-28 US US15/337,583 patent/US20170267662A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,250 patent/US20180362506A1/en not_active Abandoned
- 2018-06-13 JP JP2018112445A patent/JP2018158935A/ja active Pending
-
2019
- 2019-09-19 US US16/575,724 patent/US20200255408A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020017065A patent/JP2020079276A/ja not_active Ceased
- 2020-09-23 US US17/029,642 patent/US20210284627A1/en not_active Abandoned
-
2021
- 2021-03-03 JP JP2021033138A patent/JP2021091718A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| PE20240687A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
| PE20190446A1 (es) | Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4 | |
| AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| MX2020000261A (es) | Nuevos compuestos. | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| RU2012126129A (ru) | Производное индола и его фармацевтическое применение | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| ECSP11011200A (es) | Derivados de oxadiazale como agonista de los receptores s1p1 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |